Cargando…

Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer

BACKGROUND: Regorafenib and its metabolites may inhibit the activities of several CYP or UDP-glucuronosyltransferase isoforms, including that of CYP2C9. Therefore, pharmacological agents that are CYP2C9 substrates may show elevated circulating levels and enhanced drug efficacy when concurrently used...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitade, Hironori, Hiromasa-Yamasaki, Azusa, Hokkoku, Kengo, Mori, Mitsue, Watanabe, Michio, Nakai, Masuo, Yano, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937497/ https://www.ncbi.nlm.nih.gov/pubmed/27398225 http://dx.doi.org/10.1186/s40780-016-0050-y

Ejemplares similares

Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: Association between neurotoxicity and the GSTP1 polymorphism
por: KITADE, HIRONORI, et al.
Publicado: (2014)

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

FOLFIRI Is Tolerable after Subtotal Colectomy – A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer
por: Mori, Mitsue, et al.
Publicado: (2007)

Extreme Elevation of the Prothrombin Time-International Normalized Ratio due to a Probable Interaction between Warfarin and Flutamide
por: Konishi, Yasunobu, et al.
Publicado: (2019)

A case of a warfarinized renal cancer patient monitored for prothrombin time-international normalized ratio during methadone introduction
por: Yoshioka, Kaoru, et al.
Publicado: (2017)

A case of congenital prothrombin deficiency with two concurrent mutations in the prothrombin gene
por: Mansory, Eman M., et al.
Publicado: (2021)

Prothrombin Complex Concentrate for Rapid Reversal of Warfarin Anticoagulation to Allow Neuraxial Blockade
por: Skerritt, Conor, et al.
Publicado: (2014)

Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article
por: Onundarson, Pall T., et al.
Publicado: (2021)

Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding
por: Holt, Tara, et al.
Publicado: (2018)

Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
por: Go, Alan S., et al.
Publicado: (2022)

Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study
por: Schulman, Sam, et al.
Publicado: (2008)

Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
por: Chapman, Scott A, et al.
Publicado: (2014)

Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Bleeding in Neurosurgical Patients: A Single-Center Experience
por: Mačiukaitienė, Jomantė, et al.
Publicado: (2018)

Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
por: Wójcik, Cezary, et al.
Publicado: (2009)

A Novel LC‐MS/MS Assay for Quantification of Des‐carboxy Prothrombin and Characterization of Warfarin‐Induced Changes
por: Basit, Abdul, et al.
Publicado: (2020)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
por: Rech, Megan A., et al.
Publicado: (2021)

Factors contributing to poor outcome in patients on warfarin receiving 4-factor prothrombin complex concentrate in critically ill
por: Mishra, Ajay Kumar, et al.
Publicado: (2021)

Drug interactions between ALK inhibitors and warfarin with concurrent use of bucolome: a case report
por: Kato, Takashi, et al.
Publicado: (2023)

Prothrombin Gene G20210A Mutation in Acute Deep Venous Thrombosis Patients with Poor Response to Warfarin Therapy
por: Attia, F.M, et al.
Publicado: (2009)

Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays
por: Bordeleau, Simon, et al.
Publicado: (2015)

Evaluation of fixed dose four-factor prothrombin complex concentrate for warfarin reversal at a level 1 trauma center
por: Drone, H, et al.
Publicado: (2015)

Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage
por: Corio, Jessica L., et al.
Publicado: (2018)

A Rare Case of Skin Necrosis Following Extravasation of Prothrombin Complex Concentrate (PCC) Infusion During Warfarin Reversal
por: Smith, Emma C, et al.
Publicado: (2023)

A Rare Case of Regorafenib-Induced ST-Elevation Myocardial Infarction
por: Karki, Sadichhya, et al.
Publicado: (2023)

Elevated international normalized ratio with the consumption of grapefruit and use of warfarin
por: Bodiford, Andrew B, et al.
Publicado: (2013)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

A super‐geriatric patient with gastrostomy underwent life‐threatening prothrombin time‐international normalized ratio prolongation by warfarin following fasting and antibiotic therapy
por: Saeki, Misa, et al.
Publicado: (2023)

Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics
por: Arbring, Kerstin, et al.
Publicado: (2013)

Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department
por: Maguire, Michelle, et al.
Publicado: (2019)

Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report
por: KAWASAKI, KENTA, et al.
Publicado: (2016)

Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
por: Margraf, David J., et al.
Publicado: (2022)

Concurrent Spontaneous Sublingual and Intramural Small Bowel Hematoma due to Warfarin Use
por: Pamukçu Günaydın, Gül, et al.
Publicado: (2015)

Early experience of seven hepatocellular carcinoma cases treated with regorafenib
por: Uchikawa, Shinsuke, et al.
Publicado: (2018)

Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study
por: Saito, Makoto, et al.
Publicado: (2017)

Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study
por: Margraf, David J., et al.
Publicado: (2020)

Warfarin Reversal With Four-Factor Prothrombin Complex Concentrate for Left Ventricular Assist Device Conversion Surgery Monitored by TEG6s: A Case Report
por: Ito, Hisakatsu, et al.
Publicado: (2022)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Warfarin/herbal drink interaction: Elevated INR: case report
Publicado: (2021)

Concurrent Hand and Penile Gangrene following Prolonged Warfarin Use; a Case Report
por: Mahdizadeh, Fatemeh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vo5uf8vor48ch42eodufg1gaq6